XCath Secures $30 Million Series C to Improve Global Outcomes in Neurovascular Care, led by Crescent Enterprises and Dr. Fred Moll.
Amount Raised
$30 Million
Round Type
Series C
Investors
Description
XCath announced the successful procurement of $30 million in Series C funding to advance its endovascular surgical robot. The funding will facilitate further development and commercialization efforts. This brings the total raised by XCath to $92 million since inception. With this financing, XCath aims to enhance access to life-saving care for patients with endovascular diseases.
Who else raised in Medical Device and Robotics around the same time
Companies in the same sectors as XCath that raised within 45 days of this round, from Fundz verified event records.
- Bioxtreme raised $15M (Funding Round) on April 21, 2026.
- Articulus Surgical raised an undisclosed amount on February 11, 2026.
- Endeavor Orthopaedics raised $3.2M (Seed) on April 24, 2026.
- Alesi Surgical raised $9.5M (Funding Round) on April 21, 2026.
- Harvard Apparatus Regenerative Technology raised $300K (Debt Financing) on April 15, 2026.
- PanTera raised $4M on March 31, 2026.
Who to call at XCath, and when
A new round usually means XCath is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day XCath raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at XCath, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at XCath. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment XCath raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
XCath raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.